» Articles » PMID: 32568823

An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes

Overview
Date 2020 Jun 23
PMID 32568823
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

A robust morphomolecular classification system for gastric carcinoma is required. A 4-tier morphologic classification is proposed, including diffuse, intestinal, tubular, and lymphoid types. A tissue microarray for mismatch repair immunohistochemistry and Epstein-Barr virus (EBV) in situ hybridization were performed in 329 gastric carcinomas. DNA flow cytometry was used to detect aneuploidy in formalin-fixed paraffin-embedded samples. Lymphoid histology was the third most common histologic pattern at our institute and strongly associated with EBV infection and PMS2/MLH1-deficiency (both P<0.001). HER2 overexpression and SATB2 expression more frequently occurred in intestinal histology (both P<0.001). Loss of ARID1A expression was strikingly associated with lymphoid histology (P<0.001) and negative E-cadherin expression was correlated with diffuse histology (P=0.001). Programmed death-ligand 1 expression was most frequently present in lymphoid-type gastric carcinoma than other histologic subtypes and correlated with the molecular features of PMS2/MLH1-deficiency and EBV infection (all P<0.001). Aneuploidy was detected in 53% of gastric carcinomas and was highly correlated with intestinal type and the least with the lymphoid type (P<0.001). Notably, lymphoid-type gastric carcinoma showed the best outcome, whereas tubular type showed the worst survival rate (P<0.001). We integrated aneuploidy with morphologic patterns to propose a morphomolecular classification scheme, which served as a successful and independent prognostic factor in multivariate 5-year disease-free survival analysis (P<0.001). Overall, we describe an integrated morphomolecular classification system for gastric carcinomas to effectively predict patient outcomes. This system is cost-effective and reliable and can help select target therapeutics and facilitate clinical management.

Citing Articles

The prognostic and immunomodulatory role of the MMR system in patients with stomach adenocarcinoma.

Tian Z, Yang L, Yang R, Yang W Sci Rep. 2025; 15(1):180.

PMID: 39748125 PMC: 11695722. DOI: 10.1038/s41598-024-84613-8.


Chromosomal Instability in Gastric Cancer: Role in Tumor Development, Progression, and Therapy.

Nemtsova M, Kuznetsova E, Bure I Int J Mol Sci. 2023; 24(23).

PMID: 38069284 PMC: 10707305. DOI: 10.3390/ijms242316961.


NTRK gene alterations were enriched in hepatoid or enteroblastic differentiation type of gastric cancer.

Pu X, Fu Y, Sun Q, Li L, Kwasi A, Ma Z J Clin Pathol. 2023; 77(9):608-613.

PMID: 37451841 PMC: 11474252. DOI: 10.1136/jcp-2023-208865.


The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers.

Minciuna C, Tanase M, Manuc T, Tudor S, Herlea V, Dragomir M Comput Struct Biotechnol J. 2022; 20:5065-5075.

PMID: 36187924 PMC: 9489806. DOI: 10.1016/j.csbj.2022.09.010.


Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma.

Silva A, Saito Y, Yoshikawa T, Oshima T, Hayden J, Oosting J Br J Surg. 2022; 109(3):291-297.

PMID: 35179206 PMC: 10364690. DOI: 10.1093/bjs/znab460.